Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment (2020) Busse A, Mochmann LH, Spenke C, Arsenic R, Briest F, Jöhrens K, Lammert H, et al. Journal article Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution SERIO - Side Effect Registry Immuno-Oncology Side Effect Registry for rare, severe and complex Side Effects of Immunotherapy (2020) Kramer R, Mentzer D, Erdmann M, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel S, et al. Conference contribution Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? (2020) Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, et al. Journal article Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms (2020) Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME Journal article Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow-up (Germany/Austria) registries (2020) Shah VN, Grimsmann JM, Foster NC, Dost A, Miller KM, Pavel ME, Weinstock RS, et al. Journal article CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , et al. Conference contribution Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath , Shah T, Pape UF, Truong Thanh XM, et al. Conference contribution Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers (2020) De Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J, Chakrabarty B, Landolfi S, et al. Conference contribution Palliative CT Brachytherapy in Hepatic Metastatic NET (2020) Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G, Geisel D, Pavel ME, et al. Conference contribution